Several studies have linked mutations in downstream TLR9 signaling (e.g., MYD88) or polymorphism in the TLR9 promoter to the pathogenesis of aggressive NHL10, 32 or increased NHL incidence,33 respectively. This evidence concerns the gene MYD88 and non-Hodgkin lymphoma.